Home  »  Ipo Review  »  Earum Pharmaceuticals Ipo

Let’s have a detailed review of the company and analytics of the Earum Pharmaceuticals IPO release date, IPO offer price, subscription, Earum Pharmaceuticals IPO allotment, grey market price and other details like the company’s background, its financial positions, its promoters and other related things.

Earum Pharmaceuticals is engaged in the pharmaceutical business involving marketing, trading and distribution of wide range of pharmaceutical formulation products. Stock Broker Complaints


Earum Pharmaceuticals IPO Review & Ratings

IPO Ratings & Review
Criteria Ratings
Industry Sentiments 7.5/10
Industry Ranking 7.1/10
Company Background 7.4/10
Company Reputation 7.2/10
Competitive Edge 7.7/10
Financial Statements 7.1/10
Popularity Index 7.4/10
Promoters Reputation 7.7/10
Retail Appetite 7.1/10
Top Brokers Review 7.5/10
Overall Ratings 7.3/10
Star Ratings ★★★☆☆

Summary of Earum Pharmaceuticals IPO

Earum Pharmaceuticals IPOEarum Pharmaceuticals Limited  is engaged in the pharmaceutical business involving marketing, trading and distribution of wide range of pharmaceutical formulation products. 

As per Restated Financial statements

  • For the nine (9) months period ended December 31, 2018 and fiscal 2018, 2017 and 2016, their total revenues were Rs. 3450.35 lakhs, Rs. 3584.65 lakhs, Rs. 2369.27 lakhs, and Rs. 1863.00 lakhs, respectively.
  • The net asset value per Equity Share was Rs. 164.50 and Rs. 136.46 as of Dec 30, 2018 and March 31, 2018, respectively, as per the Restated Financial Statements 
  • The net worth of the company as on March 31, is  Rs. 421.08 lakhs as per the Restated Ind AS Consolidated Summary Statement of Assets and Liabilities.
  • The Profit after Tax for the similar period mentioned above was Rs. 86.51 lakhs, Rs. 85.65 lakhs, Rs. 15.98 lakhs, and Rs. 9.76 lakhs, respectively.

The Promoters of this company are Mr. Bhumishth Narendrabhai Patel, Mrs. Payal Bhumishth PatelThe lead manager to the issue is Hem Securities Limited and the Registrar to this issue is Bigshare Services Private Limited.


Open Free* Demat A/C Now! Fill the details below

    Fill Your Details Here



    Earum Pharmaceuticals IPO Date

    The opening and the closing date of Earum Pharmaceuticals IPO is Jun 21 – Jun 26, 2019.


    Earum Pharmaceuticals IPO Subscription

    Day / Date NII RII Total Subscription
    1st Day – Jun 21 1.16x 0.02x 0.59x
    2nd Day – Jun 24 1.29x 0.25x 0.77x
    3rd Day – Jun 25 1.30x 0.32x 0.81x
    4th Day – Jun 26
    Shares Offered or Net Issue 876,000 876,000 1,752,000

    The shares subscribed by the public will be updated herein on a daily basis, once the IPO is open for subscription.


    Earum Pharmaceuticals IPO Allotment Status

    Here, you can find the Allotment Status of this IPO.

    Basis of Allotment Finalization Jul 1, 2019
    Refunds Initiation Jul 2, 2019
    Credit of Shares to Demat Account Jul 3, 2019
    Share Listing Date Jul 4, 2019

    Earum Pharmaceuticals IPO Price Band

    The face value of each share is Rs 10, but the price band of the IPO is Rs 36. 


    Earum Pharmaceuticals IPO Equity Share Offering

    This is an Initial Public Fresh Issue of 18,48,000 Equity Shares of face value of Rs. 10 each of the Company for cash at a price of Rs. 36 per Equity Share (including a share premium of Rs. 26 per Equity Share) aggregating up to Rs. 665 lakhs.


    Open Free Demat Account Now!

      Fill Your Details Here
      1. Open Demat AccountInvest in IPO


      Earum Pharmaceuticals Limited – Company Overview

      Earum Pharmaceuticals Limited was originally incorporated as “Earum Pharmaceuticals Private Limited” on July 26, 2012. On January 10, 2019, the company was converted into a Public Limited Company and consequently the name of the Company was changed from “Earum Pharmaceuticals Private Limited” to “Earum Pharmaceuticals Limited” vide a fresh Certificate of Incorporation dated January 23, 2019 provisions of the Companies Act, 1956.

      Earum Pharmaceuticals Product Line

      It is engaged in the pharmaceutical business involving marketing, trading and distribution of wide range of pharmaceutical formulation products such as anti-biotic drugs, anti-malarial drugs, anti-allergic &anti cold drugs, analgesic/ anti-pyretic & anti inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastro intestinal drugs, steroids, gynecology drugs, calcium, multivitamins, anti-oxidants and injections.

      They also offer around 125 pharmaceutical formulation products, of which around 24 products are marketed by us under their own brandname, the manufacturing of which is outsourced by them to third parties. Apart from pharmaceutical formulation products, they also deal in trading of active pharmaceutical ingredients (API’s) such as Levofloxacin Hemihdrate IP Albendazol IP, Amoxicillin Trihydrate IP etc.

      They have the registered office, corporate office and warehouse situated at Ahmedabad (Gujarat).


      Competitive Strengths of Earum Pharmaceuticals Limited:

      • Diversified Product Portfolio
      • Experienced Promoter and Management Team
      • Quality Assurance

      Business strategies of Earum Pharmaceuticals Limited:

      • Make their presence in Global Market
      • Leveraging their Marketing skills and Relationships
      • Focus on dealing in quality standard products
      • To build-up a professional organization
      • Develop cordial relationship with their Suppliers, Customer and employees

      Earum Pharmaceuticals Limited – Financial Statements

      A quick look into the past financial performance of the company to understand its performance of business and evaluate the growth prospectus:

      Financial Summary Earum Pharma IPO

      On the basis of Standalone statement:

      Amount (in INR & lakhs)
      30-Dec-18 31-Mar-18 31-Mar-17 31-Mar-16
      Total Assets 2,741.00  22,492.59 1,108.45 878.71
      Total Revenue 3,450.35  3,584.65 2,369.27 1,863.00
      Total Expense 3,330.69  3,460.51 2,345.60 1,846.96
      Profit After Tax 86.51  85.65 15.98  9.76

      Earnings per Equity Share (in lakhs)

      30-Dec-18 31-Mar-18 31-Mar-17 31-Mar-16
      Basic & Diluted 2.00 3.50 1.06 0.88

      From the above statements, one could find that the Earum Pharmaceuticals Limited may perform well.


      Earum Pharmaceuticals IPO – Promoters

      The Promoters of this company are:

      • Mr. Bhumishth Narendrabhai Patel
      • Mrs. Payal Bhumishth Patel

      List of Related Parties (Key Managerial Personnel)

      • Mr. Bhumishth Narendrabhai Patel – Managing Director
      • Mrs. Payal Bhumishth Patel – Whole Time Director
      • Ms. Ashna Sangwan – CFO
      • Mr. Mr. Parsotam Kantilal Purohit – Compliance officer & CS

      Interest in promotion of the Company

      Company is currently promoted by the Promoters in order to carry on its present business. Promoters are interested in the Company to the extent of their shareholding and directorship of the Individual Promoter in the Company and the dividend declared, if any, by the Company. The Promoters are interested in the transactions entered into the Company and the Promoter Group.

      Property Interest

      The promoters along with the promoter group will continue to hold collectively some percentage of the equity share capital of the company.

      As a result of the same, they will be able to exercise significant influence over the control of the outcome of the matter that requires approval of the majority shareholders vote.

      Interest in Intellectual Rights of the Company

      Promoters has not shown any interest in acquiring the intellectual rights of the company.


      Earum Pharmaceuticals IPO Offer Details or Earum Pharma IPO Issue Details

      Particulars  No. Of Equity Shares
       Equity Shares Offered  18,48,000 Equity Shares aggregating up to Rs. [●] lakhs
       Of which:
       Reserved for Market Makers  [●] Equity Shares aggregating up to Rs. [●] lakhs
       Net Issue to the Public  [●] Equity Shares aggregating up to Rs. [●] lakhs
       Of which:
       Retail Investors Portion  At least [●] Equity Shares aggregating up to Rs. [●] lakhs will be available for allocation to Retail Individual Investors
       Non-Retail Investors Portion Not more than [●] Equity Shares aggregating up to Rs. [●] lakhs will be available for allocation to investors other than Retail Individual Investors including Non- Institutional Investors and Qualified Institutional Buyers
       Equity Shares outstanding prior to the Issue 43,19,910 Equity Shares
       Equity Shares outstanding after the Issue Upto 61,67,910 Equity Shares of face value of Rs. 10 each

      Earum Pharma IPO Issue Object

      These are the IPO Issue Objects of the company

      • Funding the Working Capital requirements of the Company:
      •  Repayment/ pre-payment of certain unsecured loans availed from banks and financial institutions by the company

      Earum Pharma IPO – Basis of the Offer Price

      The issue price is determined by the company in consultation with the Lead manager on the basis of the following qualitative and quantitative factors.

      Qualitative factors are:

      • Diversified Product Portfolio
      • Experienced Promoter and Management Team
      • Quality Assurance

      The relevant quantitative factors are:

      Basic & Diluted EPS RONW in % NAV (Rs.)
      31-Mar-16 0.88 7.14
      31-Mar-17 1.06 10.48
      31-Mar-18 3.50 20.34
      136.46
      • Price to Earnings (P/E) ratio in relation to Issue Price of [●]
      Particulars P/E ratio
      Highest 30.96
      Average 30.96
      Lowest 30.96

      Competitive Peers Earum Pharmaceuticals IPO

      Sr. No.  Particulars Face Value  (in Rs.)  EPS (In Rs.) P/E Ratio RONW (%)  NAV (In Rs.)
      1 Earum Pharmaceuticals Limited 10 3.50 [●] 20.34 136.86
      2 Vaishali Pharma Ltd.* 10 1.4 30.96 3.87 25.83

      Earum Pharmaceuticals IPO Lead Managers

      Lead Managers
      HEM SECURITIES LIMITED
      904,A Wing, Naman Midtown, Senapati Bapat Marg, Elphinstone Road, Lower Parel,
      Mumbai-400013, India
      Tel. No.: +91- 022- 49060000 Fax No.: +91- 022- 22625991
      Website: www.hemsecurities.com
      Email: ib@hemsecurities.com
      Investor Grievance Email: redressal@hemsecurities.com
      Contact Person :Mr. Anil Bhargava
      SEBI Regn. No. INM000010981

      Earum Pharmaceuticals IPO Registrar to offer

      Registrar to the Offer
      BIGSHARE SERVICES PRIVATE LIMITED,
      Address -1st Floor, Bharat Tin Works Building,
      Opp. Vasant Oasis, Makwana Road,
      Marol, Andheri East, Mumbai – 400059
       – 400072. India. Tel. No. – 022 – 62638200
      Website: www.bigshareonline.com/ Email: ipo@bigshareonline.com
      Investor Grievance Email: investor@bigshareonline.com
      Contact Person: Mr. Ashok Shetty Regn. No. INR000001385

      Other Details of Earum Pharma IPO

      • Statutory Auditor –M/s. J M Patel & Bros.
      • Peer Review Auditor – M/s. J M Patel & Bros.
      • Bankers to the Company – State Bank of India

      Earum Pharma IPO Review by Top 10 Stock Brokers

      Top Stock Brokers Review Company Reputation Competitive Edge Financial Statement Popularity Index Promoters Reputation
      Angel Broking 7.2/10 7.4/10 7.2/10 7.1/10 7.1/10
      Sharekhan 7.2/10 7.1/10 7.7/10 7.1/10 7.5/10
      Kotak Securities 7.3/10 7.2/10 7.4/10 7.1/10 7.2/10
      ICICI Direct 7.4/10 7.3/10 7.7/10 7.2/10 7.1/10
      IIFL 7.2/10 7.2/10 7.8/10 7.0/10 7.1/10
      Edelweiss 7.2/10 7.4/10 7.3/10 7.3/10 7.2/10
      Zerodha 7.3/10 7.1/10 7.2/10 7.1/10 7.0/10
      5Paisa 7.1/10 7.1/10 7.3/10 7.1/10 7.1/10
      Karvy 7.3/10 7.4/10 7.2/10 7.1/10 7.1/10
      Motilal Oswal 7.1/10 7.1/10 7.7/10 7.3/10 7.2/10

      Earum Pharmaceuticals IPO Grey Market Premium

      The Earum Pharmaceuticals IPO Grey Market Premium price is Rs X, the Kostak rate is Rs X and the Subject to Sauda is X. 


      Open Free* Demat A/C Now! Fill the details below

        Fill Your Details Here


        Earum Pharmaceuticals IPO News

        News 1 – IPO ISSUE OPENS SOON [Download Prospectus]


        Market Guide


        Featured Topics

        Get 90% Discount on Brokerage Now! Open Demat Account